ATRIPLA combines two nucleoside reverse transcriptase inhibitors (NRTIs) and one
non-nucleoside reverse transcriptase inhibitor (NNRTI) in one pill.
The first HIV regimen in one pill daily. ATRIPLA may be taken alone or with other HIV medicines.
With the power of three HIV medicines in one pill, ATRIPLA offers an entire HIV regimen in a single daily dose, for many patients.
ATRIPLA is the #1 prescribed HIV regimen.*
- ATRIPLA is the only 1 pill daily HIV regimen with 3 DHHS-preferred† meds for patients new to therapy.
- ATRIPLA is proven to lower viral load to undetectable‡
and helps raise T-cell (CD4+) count to help control HIV through 3 years of a clinical study
in patients new to therapy.
- Through 3 years, 71% of patients taking the meds in ATRIPLA had undetectable‡ viral loads versus 58% for
COMBIVIR (lamivudine/zidovudine) + SUSTIVA
- At Year 3, the average increase of CD4+ cell count was 312 cells/mm3 for patients taking the meds in ATRIPLA versus 271 cells/mm3 for COMBIVIR + SUSTIVA
The long-term effects (beyond 3 years) of ATRIPLA are not known at this time. People taking ATRIPLA may still get opportunistic
infections or other conditions that happen with HIV-1 infection.
ATRIPLA does not cure HIV-1 infection or AIDS
and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections.
MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA
These are not all the medicines that may cause problems if you take ATRIPLA. Tell your healthcare provider
about all prescription and nonprescription medicines, vitamins, or herbal supplements you are taking or plan
- Do not take ATRIPLA if you are taking the following medicines because serious and
life-threatening side effects
may occur when taken together: Vascor® (bepridil),
Propulsid® (cisapride), Versed® (midazolam), Orap®
(pimozide), Halcion® (triazolam), or ergot medications (for example, Wigraine® and Cafergot®).
- ATRIPLA should not be taken with: Combivir® (lamivudine/zidovudine),
(emtricitabine/rilpivirine/tenofovir disoproxil fumarate),
EMTRIVA® (emtricitabine), Epivir® or Epivir-HBV®
Epzicom® (abacavir sulfate/lamivudine), Trizivir® (abacavir
sulfate/lamivudine/zidovudine), TRUVADA® (emtricitabine/tenofovir DF), or VIREAD® (tenofovir DF), because
they contain the same or similar active ingredients as ATRIPLA. ATRIPLA should not be used with SUSTIVA® (efavirenz) unless recommended by your healthcare provider.
- Vfend® (voriconazole) should not be taken with ATRIPLA since it may lose its effect or may increase the chance
of having side effects from ATRIPLA.
- Do not take St. John’s wort (Hypericum perforatum), or products containing St. John’s wort with
ATRIPLA. Taking St. John’s wort may decrease ATRIPLA levels and lead to increased viral load, and possible
resistance to ATRIPLA or cross-resistance to other
- ATRIPLA should not be used with HEPSERA® (adefovir dipivoxil).
Ask your doctor if ATRIPLA is right for you, and see your healthcare provider regularly. Individual results may vary.
Please click here
for Important Safety Information, including information on buildup of lactic acid in the blood
, serious liver problems, and sudden worsening of hepatitis B virus
Please click on each product's name to view Full Prescribing Information, including Boxed WARNINGS
, and Full Prescribing Information for SUSTIVA